VivoSim Labs, Inc. (VIVS) stock forecast & analysis
0.2608
NasdaqCM · USDDelayed by 15 minutes
Down: -0.0307, -10.5%
0.2428Down: -0.0180, -6.9%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.2800
- Previous close
- 0.2915
- Day range
- 0.2435 – 0.3808
- 52-week range
- 0.1200 – 3.40
- Volume (shares)
- 147.19M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 20.28M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.56
- Market cap
- 5.29M
Market Scanner’s AI analysis of VivoSim Labs, Inc. (VIVS), updated November 2026: VivoSim Labs' recent coverage focused on a significant price spike driven by a commercial agreement and guidance raise, contrasted with a negative long-term technical trend.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of VivoSim Labs, Inc. (VIVS) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
VivoSim Labs' recent coverage focused on a significant price spike driven by a commercial agreement and guidance raise, contrasted with a negative long-term technical trend.
Recent analyses for VivoSim Labs covered a dramatic single-session price increase on extremely high volume, which broke a six-week decline. This spike occurred alongside news of a seven-figure commercial agreement with a pharmaceutical company and a raise in fiscal 2027 revenue growth expectations. However, trend indicators and longer-term moving averages still point to a negative technical picture.
VIVS news & sentiment
News headlines focused on a significant commercial agreement and a raised revenue outlook, driving a sharp price increase. Social media discussion was not covered in the provided notes.
VIVS technical picture
A six-week decline was broken by a single session of extreme volume, pushing the price near its session high. However, trend indicators still point down, suggesting the one-day spike may not signal a sustained reversal.
Fundamentals
The company reported minimal trailing twelve months revenue and a significantly negative return on equity. Its market capitalization is small, and it does not pay a dividend.
Factors discussed — upside
- Seven-figure commercial agreement with a top-10 pharmaceutical company announced.
- Fiscal 2027 revenue growth expectations raised.
- Single-session price increase of 142% on extreme volume.
Factors discussed — risks
- Stock price remains significantly below its 200-day moving average.
- Trend indicators still point down despite the recent price spike.
- Negative trailing twelve months EPS and return on equity.
- No specific value or term disclosed for the commercial agreement.
- Technical price action
- Commercial agreements
- Revenue guidance
- Valuation and returns
Summary updated .
VIVS technical indicators
Common technical indicators for VIVS, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.18 | Price above |
| 10-day exponential moving average | 0.18 | Price above |
| Relative strength index (14-day) | 67.55 | Neutral |
| MACD line (12/26/9) | 0.0043 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.07 – 0.24 | Price above the upper band |
Analyses
Recent VIVS.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-20 VIVS.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for VivoSim Labs, Inc.?
- The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume.
- What are the risks for VivoSim Labs, Inc.?
- Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term.
- Is VivoSim Labs, Inc. bullish or bearish?
- Recent AI analyses of VivoSim Labs, Inc. examined factors on both sides. Discussed upside: The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume. Discussed risks: Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term. These are descriptive observations, not a recommendation.
- What is the latest sentiment on VivoSim Labs, Inc.?
- News headlines focused on a significant commercial agreement and a raised revenue outlook, driving a sharp price increase. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse VivoSim Labs, Inc.?
- Every analysis of VivoSim Labs, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for VivoSim Labs, Inc.?
The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume.
What are the risks for VivoSim Labs, Inc.?
Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term.
Is VivoSim Labs, Inc. bullish or bearish?
Recent AI analyses of VivoSim Labs, Inc. examined factors on both sides. Discussed upside: The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume. Discussed risks: Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term. These are descriptive observations, not a recommendation.
What is the latest sentiment on VivoSim Labs, Inc.?
News headlines focused on a significant commercial agreement and a raised revenue outlook, driving a sharp price increase. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse VivoSim Labs, Inc.?
Every analysis of VivoSim Labs, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh VIVS.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.